FDA Inspection 1219962 — Solvias AG
The FDA completed an inspection of Solvias AG on September 1, 2023 in Kaiseraugst. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- September 1, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Kaiseraugst (Switzerland)
Additional Details
Bioanalytical BA/BE